Fujifilm has been steadily building up its regenerative medicines, with several acquisitions of companies that hold expertise in the area – by acquiring Japan Tissue Engineering in 2014 and then Wako Pure Chemical Industries the following year.
The latter company was bought from Takeda and the two have returned to partner in the space, as Fujifilm looks to establish its expertise in stem cell technology.
The partnership will focus on regenerative therapies that use stem-cells from heart muscle tissue for use in the treatment of heart failure.